Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:21791546rdf:typepubmed:Citationlld:pubmed
pubmed-article:21791546lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C0003873lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C0039198lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C0031437lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C0237753lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C0717758lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C1122087lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C1332714lld:lifeskim
pubmed-article:21791546lifeskim:mentionsumls-concept:C0392760lld:lifeskim
pubmed-article:21791546pubmed:issue10lld:pubmed
pubmed-article:21791546pubmed:dateCreated2011-9-21lld:pubmed
pubmed-article:21791546pubmed:databankReferencehttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:abstractTextTo analyse the therapeutic effects of etanercept (ETA) or adalimumab (ADA) on the numbers and phenotypes of CD4+CD25hi Tregs in RA patients.lld:pubmed
pubmed-article:21791546pubmed:languageenglld:pubmed
pubmed-article:21791546pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:citationSubsetAIMlld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:21791546pubmed:statusMEDLINElld:pubmed
pubmed-article:21791546pubmed:monthOctlld:pubmed
pubmed-article:21791546pubmed:issn1462-0332lld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:Le...lld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:VittecoqOlivi...lld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:BoyerOlivierOlld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:LequerréThier...lld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:JacquotSergeSlld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:BlacheCélineClld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:DedreuxIngrid...lld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:RoucheuxArnau...lld:pubmed
pubmed-article:21791546pubmed:authorpubmed-author:BeutheuStépha...lld:pubmed
pubmed-article:21791546pubmed:issnTypeElectroniclld:pubmed
pubmed-article:21791546pubmed:volume50lld:pubmed
pubmed-article:21791546pubmed:ownerNLMlld:pubmed
pubmed-article:21791546pubmed:authorsCompleteYlld:pubmed
pubmed-article:21791546pubmed:pagination1814-22lld:pubmed
pubmed-article:21791546pubmed:dateRevised2011-11-17lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:meshHeadingpubmed-meshheading:21791546...lld:pubmed
pubmed-article:21791546pubmed:year2011lld:pubmed
pubmed-article:21791546pubmed:articleTitleNumber and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept.lld:pubmed
pubmed-article:21791546pubmed:affiliationInserm, U905, Institut Fédératif de Recherche Multidisciplinaire surles Peptides 23, Institute for Biomedical Research, University of Rouen, Faculté de Médecine-Pharmacie, Rouen, France.lld:pubmed
pubmed-article:21791546pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:21791546pubmed:publicationTypeClinical Triallld:pubmed